Hurdles to the introduction of new therapies for immune-mediated kidney diseases

Nature Reviews Nephrology

Volumn 12, Issue 4, 2016, Pages 205-216

  Anders, Hans Joachim ^a   Jayne, David R W ^b   Rovin, Brad H ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 18; MONOCYTE CHEMOTACTIC PROTEIN 1; TAMM HORSFALL GLYCOPROTEIN; IMMUNOLOGIC FACTOR;

ANCA ASSOCIATED VASCULITIS; CREATININE BLOOD LEVEL; DISEASE COURSE; HUMAN; IMMUNE MEDIATED KIDNEY DISEASE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; KIDNEY DISEASE; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; NEPHRON; NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DEVELOPMENT; GLOMERULONEPHRITIS; IMMUNOLOGY; KIDNEY DISEASES; LUPUS NEPHRITIS; RARE DISEASES;

ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; GLOMERULONEPHRITIS; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; LUPUS NEPHRITIS; RARE DISEASES;

EID: 84955324880     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.206     Document Type: Review

References (76)

1. Machowska A., et al. Therapeutics targeting persistent inflammation in chronic kidney disease. Transl. Res. 167, 204-213 (2015
2. Weening J. J., & Jennette J. C. Historical milestones in renal pathology. Virchows Arch. 461, 3-11 (2012
3. Trachtman H., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236-1243 (2011
4. Giglio S., et al. Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. J. Am. Soc. Nephrol. 26, 230-236 (2015
5. Sadowski C. E., et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1279-1289 (2015
6. Freedman B. I., et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66, 390-396 (2014
7. Larsen C. P., et al. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J. Am. Soc. Nephrol. 24, 722-725 (2013
8. Kottgen A., et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Genet. 41, 712-717 (2009
9. Soleymanian T., et al. Non-diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome. Ren. Fail. 37, 572-575 (2015
10. Hildebrandt F. Genetic kidney diseases. Lancet 375, 1287-1295 (2010
11. Roche P. A., & Furuta K. The ins and outs of MHC class II mediated antigen processing and presentation. Nat. Rev. Immunol. 15, 203-216 (2015
12. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1-150 (2013
13. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9 (Suppl. 3), S1-S155 (2009
14. Weening J. J., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol. 15, 241-250 (2004
15. Boneparth A., & Ilowite N. T. Comparison of renal response parameters for juvenile membranous plus proliferative lupus nephritis versus isolated proliferative lupus nephritis: a cross-sectional analysis of the CARRA Registry. Lupus 23, 898-904 (2014
16. Radhakrishnan J., et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 77, 152-160 (2010
17. Miyake K., Akahoshi M., & Nakashima H. Th subset balance in lupus nephritis. J. Biomed. Biotechnol. 2011, 980286 (2011
18. Rezende G. M., et al. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria? Lupus 23, 255-262 (2014
19. Mysler E. F., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 65, 2368-2379 (2013
20. Cattran D. C., et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76, 534-545 (2009
21. Grootscholten C., et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol. Dial. Transplant. 23, 223-230 (2008
22. Rovin B. H., Parikh S. V., & Alvarado A. in Systemic Lupus Erythematosus (eds Ginzler E. M., & Dooley M. A.) 537-552 (Elsevier, 2014
23. Wilhelmus S., et al. Interobserver agreement on histopathological lesions in class III or IV lupus nephritis. Clin. J. Am. Soc. Nephrol. 10, 47-53 (2014
24. Peterson K. S., et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113, 1722-1733 (2004
25. Parikh S., et al. Characterizing the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci. Med. 2, e000112 (2015
26. Parikh S. V., Ayoub I., & Rovin B. H. The kidney biopsy in lupus nephritis: time to move beyond histology. Nephrol. Dial. Transplant. 30, 3-6 (2015
27. Rovin B. H., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 64, 1215-1226 (2012
28. McGrogan A., Franssen C. F., & de Vries C. S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol. Dial. Transplant. 26, 414-430 (2011
29. Stone J. H., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010
30. Ruggenenti P., et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J. Am. Soc. Nephrol. 26, 2545-2558 (2015
31. López-Gómez J. M., & Rivera F. Renal biopsy findings in acute renal failure in the cohort of patients in the Spanish Registry of Glomerulonephritis. Clin. J. Am. Soc. Nephrol. 3, 674-681 (2008
32. Gadegbeku C. A., et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 83, 749-756 (2013
33. Coppo R., et al. VALIGA study of the ERA-EDTA Immunonephrology Working Group. Kidney Int. 86, 828-836 (2014
34. Jayne D., & Rasmussen N. Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. Nephrol. Dial. Transplant. 30 (Suppl. 1), i1-i7 (2015
35. Morrish A. T., et al. Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney Int. 85, 23-30 (2014
36. Walsh M., et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 14, 73 (2013
37. Howman A., et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744-751 (2013
38. Fervenza F. C., et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron 130, 159-168 (2015
39. Dooley M. A., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886-1895 (2011
40. de Zeeuw D., et al. The effect of CCR2 inhibitor CCX140 B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 3, 687-696 (2015
41. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02222155?term=NCT02222155& rank=1 (2015
42. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01547897?term=NCT01547897& rank=1 (2014
43. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01919346?term=NCT01919346& rank=1 (2015
44. Boumpas D. T., et al. A short course of BG9588 (anti CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003
45. Appel G. B., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103-1112 (2009
46. Holderied A., & Anders H. J. Animal models of kidney inflammation in translational medicine. Drug Discov. Today Dis. Models 11, 19-27 (2014
47. Hirst J. A., et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS ONE 9, e98856 (2014
48. Llovera G., et al. Results of a preclinical randomized controlled multicenter trial (pRCT): anti CD49d treatment for acute brain ischemia. Sci. Transl. Med. 7, 299ra121 (2015
49. Group A. T. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. 66, 3096-3104 (2014
50. Condon M. B., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280-1286 (2013
51. D'Acquisto F. M., May J., & Ghosh S. Inhibition of nuclear factor kappa B (NF B): an emerging theme in anti-inflammatory therapies. Mol. Interv. 2, 22-35 (2002
52. Lourenco E. V., et al. Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol. 66, 674-685 (2014
53. Jayne D., et al. The pharmacokinetics of laquinimod and mycophenolate mofetil during treatment of active lupus nephritis. Presented at the American Society of Nephrology Annual Meeting, Atlanta (2013
54. Enia G., et al. Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. Int. J. Artif. Organs 13, 98-102 (1990
55. Jansen N. J., et al. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur. J. Cardiothorac. Surg. 5, 211-217 (1991
56. Malvar A., et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfv296 (2015
57. Dallera M., et al. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res. (Hoboken) 63, 351-357 (2011
58. Dallera M., et al. Predictors of long-term renal outcome in Lupus Nephritis Trials: lessons learned from the Euro-Lupus Nephritis Cohort. Arthritis Rheumatol. 67, 1305-1313 (2015
59. Tamirou F., et al. Long-term follow up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis 2014 206897 (2015
60. Beck L. H. Jr, et al. Rituximab-induced depletion of anti PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543-1550 (2011
61. Reich H. N., et al. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 18, 3177-3183 (2007
62. Sharma A., Mucino M. J., & Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin. Pract. 127, 94-100 (2014
63. Li Y., et al. Urinary biomarkers in lupus nephritis. Autoimmun. Rev. 5, 383-388 (2006
64. Suthanthiran M., et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N. Engl. J. Med. 369, 20-31 (2013
65. Enghard P., et al. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann. Rheum. Dis. 73, 277-283 (2014
66. Kopetschke K., et al. The cellular signature of urinary immune cells in lupus nephritis: new insights into potential biomarkers. Arthritis Res. Ther. 17, 94 (2015
67. Murray P. T., et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 85, 513-521 (2014
68. Kashani K., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 17, R25 (2013
69. Luyckx V. A., & Brenner B. M. The clinical importance of nephron mass. J. Am. Soc. Nephrol. 21, 898-910 (2010
70. Luyckx V. A., & Brenner B. M. Birth weight, malnutrition and kidney-associated outcomes-a global concern. Nat. Rev. Nephrol. 11, 135-149 (2015
71. Beeman S. C., et al. MRI-based glomerular morphology and pathology in whole human kidneys. Am. J. Physiol. Renal Physiol. 306, F1381-F1390 (2014
72. Risch L., et al. The serum uromodulin level is associated with kidney function. Clin. Chem. Lab. Med. 52, 1755-1761 (2014
73. Torffvit O., Kamper A. L., & Strandgaard S. Tamm-Horsfall protein in urine after uninephrectomy/transplantation in kidney donors and their recipients. Scand. J. Urol. Nephrol. 31, 555-559 (1997
74. Furie R., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 66, 379-389 (2014
75. Jones R. B., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220 (2010
76. Fellstrom B. C., et al. The NEFIGAN Trial: NEFECON, a novel targeted release formulation of budesonide, reduces proteinuria and stabilizes eGFR in IgA nephropathy patients at risk of ESRD. (abstract), J. Am. Soc. Nephrol. 26, HI OR04.72 (2015